The mechanisms underlying the opposing TGF-β effects in cancer cells, being both pro-oncogenic and tumor suppressive, remain a significant challenge for inhibition of the pathway as a feasible cancer therapeutic strategy in the clinic. Here, TGFB1 is linked to cancer.